Estramustine 140mg capsules
A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Estramustine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Estramustine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 10 · Randomised trials: 8 · 1977–2019
Showing the 50 most relevant studies, sorted by most relevant.
K. Fizazi, G. Hudes, W. Berry, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006
Karim Fizazi, Laura Faivre, F. Lesaunier, et al.
The Lancet Oncology, 2015
- Docetaxel
- Androgen Antagonists
- Antineoplastic Combined Chemotherapy Protocols
M. Galsky, E. Small, W. Oh, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Castration
K. Fizazi, A. le Maître, G. Hudes, et al.
The Lancet. Oncology, 2007
- Castration
- Antineoplastic Combined Chemotherapy Protocols
- Estramustine
Masanori Noguchi, Tatsuyuki Kakuma, Hirotsugu Uemura, et al.
Cancer Immunology Immunotherapy, 2010
- Antineoplastic Combined Chemotherapy Protocols
- Estramustine
- Lymphopenia
Pan Song, Chuiguo Huang, Yan Wang
International journal of surgery, 2018
- Taxoids
- Estramustine
- Mitoxantrone
D. Berry, C. Moinpour, Caroline S. Jiang, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006
- Palliative Care
- Docetaxel
- Antineoplastic Combined Chemotherapy Protocols
W. Qi, Zan Shen, Yang Yao
Journal of Cancer Research and Clinical Oncology, 2011
D. Petrylak, C. Tangen, M. Hussain, et al.
The New England journal of medicine, 2004
- Docetaxel
- Adenocarcinoma
- Antineoplastic Combined Chemotherapy Protocols
Diane Savarese, Susan Halabi, Vera Hárs, et al.
Journal of Clinical Oncology, 2001
- Taxoids
- Docetaxel
- Antineoplastic Combined Chemotherapy Protocols
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
20 hours
Mechanism
Estramustine is a derivative of estradiol with a nitrogen mustard moiety.
Food interactions
2 warnings
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
20 hours
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 508 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter.
Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP.
Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3 .
PMID:17922032
Maintains neuronal survival in response to ischemic reperfusion injury when in the presence of circulating estradiol (17-beta-estradiol/E2) (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC L01XX11
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Estramustine
Additional database identifiers
Drugs Product Database (DPD)
2103
ChemSpider
227635
BindingDB
50333646
ZINC
ZINC000004099032
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3468
GenAtlas
ESR2
GeneCards
ESR2
GenBank Gene Database
AB006590
GenBank Protein Database
2911152
Guide to Pharmacology
621
UniProt Accession
ESR2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3467
GenAtlas
ESR1
GeneCards
ESR1
GenBank Gene Database
X03635
GenBank Protein Database
31234
Guide to Pharmacology
620
UniProt Accession
ESR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6839
GenAtlas
MAP2
GeneCards
MAP2
GenBank Gene Database
U01828
GenBank Protein Database
409875
UniProt Accession
MTAP2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6835
GenAtlas
MAP1A
GeneCards
MAP1A
GenBank Gene Database
U38291
GenBank Protein Database
1790878
UniProt Accession
MAP1A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q412939), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.